Background Amputations in people with type 2 diabetes mellitus substantially impair their quality of life and impose high costs on health-care systems. Our aim was to assess the eff ect of fenofi brate on amputation events in a large cohort of patients with type 2 diabetes.
Introduction
Diabetes mellitus is the leading cause of non-traumatic lower-extremity amputations in the developed world. In the USA in 2001, at least one amputation due to diabetes occurred every 2 h, with an annual cost exceeding US$1·6 billion. 2, 3 Despite rigorous management of reversible factors, probably around one in ten patients with diabetes will eventually need at least one amputation. Neither control of glycaemia or blood pressure nor lowering of cholesterol has prevented the risk of amputation, underscoring the importance of assessing the management of other potential risk factors. Any further therapeutic option to prevent the morbidity and mortality associated with amputation would be highly desirable.
The aim of the Fenofi brate Intervention and Event Lowering in Diabetes (FIELD) study was to assess whether long-term lipid-lowering treatment with fenofi brate could reduce adverse macrovascular and microvascular outcomes in patients with type 2 diabetes, including amputations. 4 Previously, we found that fenofi brate had a favourable eff ect on microvascular disease in terms of the need for laser therapy for diabetic retinopathy, 5 beyond what could be expected from a moderate observed reduction in blood pressure. The eff ect of fenofi brate treatment was independent of haemoglobin A 1c (HbA 1c ) and concomitant medications, and unlikely to be related to the drug's lipid-lowering eff ects. 6 The study reported here analysed the eff ect of fenofi brate on lower-limb amputation events, and investigated the diff erential eff ects of this treatment on major and minor amputations with and without associated large-vessel disease.
Methods Patients
The design and main results of the FIELD study, including safety profi le, have been published elsewhere. 4, 5 Briefl y, patients aged 50-75 years were eligible for inclusion if they had a diagnosis of type 2 diabetes according to WHO criteria, an initial plasma total cholesterol concentration between 3·0 mmol/L and 6·5 mmol/L plus a total cholesterol/HDL-cholesterol ratio of 4·0 or more, or a plasma triglyceride concentration between 1·0 mmol/L and 5·0 mmol/L, without needing lipid-modifying treatment at study entry. Individuals with renal impairment, chronic liver disease, symptomatic gallbladder disease, or those who had experienced a cardiovascular event within the 3 months before recruitment were excluded.
All patients provided written informed consent, and the study protocol was approved by local and national ethics committees in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
Randomisation and masking
A central telephone computer randomisation service that used dynamic balancing 7 to stratify patients according to important prognostic variables was used to randomly assign patients to intervention or control. All investigators and staff , except the authorised study statistician, were masked to treatment allocation both before and after randomisation. The success of masking was not formally assessed.
Procedures
9795 patients were enrolled and randomly assigned to receive once-daily micronised fenofi brate 200 mg (Laboratoires Fournier, Dijon, France; n=4895) or matching placebo (n=4900). Patients were followed up at 4-6-month intervals for a median follow-up of 5 years, and all study outcomes and serious adverse events were recorded. Non-traumatic amputation was a prespecifi ed tertiary endpoint. All non-traumatic amputations that occurred during study follow-up (on-study amputations) were reviewed separately by two clinicians who were masked to treatment allocation (KR, LPL), and any discrepancies were resolved by mutual agreement. All available baseline and on-study lower-limb angiograms and duplex ultrasounds of patients who had an amputation were reviewed for this analysis, but vascular status was not routinely measured at baseline in this study, or obtained thereafter for those who did not have an amputation. Major amputations were defi ned as those above the ankle and minor amputations as those below the ankle. 8 An additional classifi cation based on the cause of amputation was also devised. The fi rst group consisted of amputations of digits and forefoot without previous or concurrent large-vessel disease (including angioplasty and bypass surgery) in the same limb or evidence of causative embolism; these amputations were classifi ed as minor amputations without known large-vessel disease and were judged to be related to microvascular disease. The second group consisted of major amputations as well as minor amputations with documented large-vessel disease in the aff ected limb or evidence of embolism. These amputations were judged to be related to atherosclerotic disease of the major peripheral arteries.
Statistical analysis
The study off ered 80% power to detect an observed 22% reduction in cardiovascular events. 4 All analyses Data are number (%), mean (SD), or median (IQR). For further details see reference 5. *Reported at visit 1 (screening visit). †Mean of pre-randomisation visits for lipids, haemoglobin A 1c , and creatinine. ‡Microalbuminuria defi ned as urine albumin/ creatinine ratio ≥2·5 mg/mmoL and <25 mg/mmoL for men, and ≥3·5 mg/mmoL and <35 mg/mmoL for women; macroalbuminuria defi ned as urine albumin/creatinine ratio ≥25 mg/mmoL for men and ≥35 mg/mmoL for women. were done on an intention-to-treat basis. Baseline characteristics were analysed with χ² tests for categorical variables, t tests, or analysis of variance for continuous variables, or, if the distribution of the data was not normal, by Wilcoxon rank-sum tests (two-way analysis) or Kruskal-Wallis tests (three-way analysis). Proportional hazards regression was used to compute hazard ratios (HRs) and 95% CIs 9,10 to assess the eff ect of fenofi brate treatment on the time to amputation (the proportional hazards assumption was assessed by use of the Harrell-Lee test
11
). Where appropriate, p values were computed with the log-rank test. 10 Cumulative hazard curves of the time to the fi rst amputation according to the amputation classifi cation, and by treatment group, were calculated by use of the Kaplan-Meier method.
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For multiple event analysis, a Poisson model on the number of amputations was used and adjusted for months of observation and overdispersion, 12 by use of the Pearson method. 13 The Poisson analysis yielded an incidence rate ratio (analogous to the HR) that refl ected the change in event rate per unit time for the fenofi brate group relative to the placebo group. A basic risk model was developed to identify the most important predictors of amputations. Variables in the model were initially determined by use of backwards selection of all baseline characteristics in table 1 plus fi brinogen and homocysteine in a proportional hazards model, and then confi rmed by exhaustive search methods.
14 The possibility of over-fi tting because of the large number of potential predictors assessed and the small number of events was examined by calculating the heuristic shrinkage factor.
11 The shrinkage factor of 0·9 indicates that the degree of over-fi tting was negligible. Since only fi ve patients, none of whom had undergone amputation, had any missing data, no statistical adjustment was made for this. All statistical inferences were drawn with a two-sided p value of 0·05. Results are presented unadjusted for multiple comparisons.
15 SAS (version 9.1) and ACCORD (Analysis of Censored and Correlated Data; version 1.6.3, 2008) software was used for the analyses. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN64783481.
Role of the funding source
Two non-voting representatives of the main sponsor attended meetings of the management committee. The sponsors of the study had no role in data collection or data analysis. The authors had full access to all the data in the study. The authors and study management committee had fi nal responsibility for the decision to submit the manuscript for publication. Figure 1 shows the trial profi le, and table 1 the baseline characteristics of the study participants. 115 patients had lower-limb amputations due to diabetes, of whom 47 had more than one amputation (ranging from two to six). All patients who reported a non-traumatic amputation were followed up until the completion of the study. Additionally, there were three cases of amputation (all in patients assigned to placebo) that were not related to diabetes (a fi nger amputation secondary to known Raynaud's disease, and two small-toe amputations secondary to claw toe deformity and not related to diabetic neuropathy); these cases were therefore excluded from any further analysis.
Results
Baseline characteristics diff ered between patients who had on-study amputations, those who had other cardiovascular events, and those who had neither event (table 2) . Patients who had on-study amputations were more likely to be male, to be taller, or smoke, and had a longer median duration of diabetes than patients from the other two groups. They were also more likely to have reported previous cardiovascular disease (myocardial infarction, angina, coronary revascularisation, stroke, or peripheral vascular disease) or microvascular disease at baseline (including retinopathy, neuropathy, and nephropathy). Furthermore, occurrence of microalbuminuria and macroalbuminuria, and plasma HbA 1c were all higher in patients who had amputations than in those who had other cardiovascular events or had neither event. Mean lipid concentrations diff ered, but by no more than 0·2 mmol/L (table 2). Patients with amputations had more prescriptions at baseline of angiotensin-converting enzyme inhibitors, and a higher proportion used insulin than patients in the other two groups, refl ecting their longer diabetes duration, worse glycaemic control, and higher occurrence of microvascular and macrovascular complications. Age at visit 1 (years) 65 (6) 64 (7) 62 (7) 39 patients had only minor amputations without large-vessel disease in the aff ected limb and the remaining 76 had at least one major or minor amputation with large-vessel disease (table 3) . Patients whose amputations were all minor without large-vessel disease were similar in most respects to others with amputations, except that they were a mean of 3 years younger, and had a higher body-mass index and a higher frequency of microvascular disease at baseline (in particular neuropathy). Analysis of the amputations according to the causative classifi cation showed no signifi cant diff erence in baseline medication between groups.
Of the 115 patients who had one or more non-traumatic amputations due to diabetes, 45 had been allocated to fenofi brate and 70 to placebo (fi gure 2). The risk of a fi rst non-traumatic amputation was lower in the fenofi brate group than in the placebo group (HR 0·64, 95% CI 0·44-0·94; p=0·02; fi gure 2 and fi gure 3). This fi nding refl ects the lower risks of minor amputations associated with fenofi brate compared with placebo (HR 0·54, 0·34-0·85; p=0·007). However, the risk of major amputations did not diff er signifi cantly between groups (HR 0·93, 0·53-1·62; p=0·79; fi gure 2 and fi gure 3). Figure 2 shows that the risk of a fi rst minor amputation without associated large-vessel disease was lower in the fenofi brate group than in the placebo group; however, the risk of a fi rst major or minor amputation with large-vessel disease did not diff er between treatment groups. The decrease in fi rst diabetes-related amputations seemed to emerge after only 1·5 years of fenofi brate use, with continued divergence of the cumulative hazard curves over the mean 5-year follow-up period (fi gure 3).
The eff ect of fenofi brate on a fi rst amputation was similar in those taking and not taking an angiotensinconverting enzyme inhibitor or angiotensin-receptor blocker at baseline (p=0·4 for heterogeneity of treatment eff ect). Similarly, the eff ect of fenofi brate did not diff er between those with good (HbA 1c <7·0%) or poor (HbA 1c ≥7·0%) glycaemic control (p=0·6 for heterogeneity of treatment eff ect) or between those with or without ¶Mean of pre-randomisation visits for lipids, haemoglobin A 1c , and creatinine. ||Men: HDL cholesterol concentration <1·03 mmol/L and triglyceride concentration ≥1·7 mmol/L; women: HDL cholesterol concentration <1·29 mmol/L and triglyceride concentration ≥1·7 mmol/L. **Microalbuminuria defi ned as urine albumin/creatinine ratio ≥2·5 mg/mmoL and <25 mg/mmoL for men, and ≥3·5 mg/mmoL and <35 mg/mmoL for women. † †Macroalbuminuria defi ned as urine albumin/creatinine ratio ≥25 mg/mmoL for men and ≥35 mg/mmoL for women. Table 3 : Baseline characteristics of patients who had a lower-limb amputation, by presence of large-vessel disease dyslipidaemia (ie, men: HDL cholesterol concentration less than 1·03 mmol/L and triglyceride concentration 1·7 mmol/L or more; women: HDL cholesterol concentration less than 1·29 mmol/L and triglyceride concentration 1·7 mmol/L or more; p=0·5 for heterogeneity of treatment eff ect).
Of the 190 non-traumatic diabetes-related amputations in total, 73 occurred in patients assigned to fenofi brate and 117 in patients assigned to placebo. This result represents a further 28 amputations in 18 patients assigned to fenofi brate compared with 47 further amputations in 29 patients assigned to placebo. When multiple amputations per patient were considered, the HR for the eff ect of fenofi brate treatment on the number of amputations was 0·63 (0·40-0·97; p=0·040; fi gure 2).
The strongest predictors of a fi rst on-study amputation in a multivariable model were a history of previous non-traumatic amputation or diabetic skin ulcer, neuropathy, or previous peripheral vascular disease. HRs were 5·6 (3·6-8·6) for previous amputation or skin ulcer, 2·7 (1·8-4·0) for neuropathy, and 2·5 (1·7-3·9) for peripheral vascular disease (all p<0·0001). Non-modifi able factors of height and age were also predictive: the HR for height (per 10 cm) was 1·6 (1·3-2·0) and for age (per each 5 additional years) was 1·3 (1·2-1·5; also both p<0·0001). Other predictors included current smoking, albuminuria, HbA 1c (per 1% higher level), retinopathy, and percutaneous transluminal coronary angioplasty (data not shown). None of the lipid variables (total and HDL cholesterol concentrations, triglycerides) were signifi cantly associated with amputation in multivariable analysis and therefore none remained in the fi nal model. Adjusted for these signifi cant risk factors, the HR for the eff ect of fenofi brate treatment on risk of a fi rst diabetes-related amputation was 0·63 (0·43-0·92; p=0·016). This fi nding represents an absolute risk reduction of about 0·5% (95% CI 0·1-0·9). Serious adverse events associated with fenofi brate treatment have been reported elsewhere.
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Discussion
This study showed that amputation risk in patients with type 2 diabetes was lower in patients assigned to treatment with long-term fenofi brate than in those assigned to placebo. The cumulative hazard curves showed a reduction in amputation rates that seemed to emerge after just 1·5 years of fenofi brate use. The reduction in the risk of minor amputation where there was no known large-vessel disease was most striking, by contrast with a non-signifi cant reduction for major or large-vessel amputations. This analysis substantiates the established macrovascular 5 and microvascular (albuminuria 5 and retinopathy 6 ) benefi ts of fenofi brate use, which should also be considered in calculating the economic benefi ts of such treatment.
The number of patients needed to treat (NNT) with fenofi brate over 5 years to prevent at least one amputation in one patient is 197, but is 25 for someone with previous foot ulcer and albuminuria. These results compare with NNTs with fenofi brate of 17 and 90 to prevent laser treatment for retinopathy in patients with and without a history of retinopathy, respectively, 6 68 to prevent progression of albuminuria, 5 and 71 and 23 to prevent one or more cardiovascular events overall and in those with marked dyslipidaemia, respectively.
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These eff ects on amputation occurred in patients on optimum medical treatment (by current practice standards) to control risk factors that altered the progression of their diabetes. HbA 1c did not change substantially from baseline in either treatment group over the 5-year study period (data not shown). Most importantly, the treatment eff ects of fenofi brate were irrespective of the level of glycaemic control and background use or not of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, strongly suggesting that the drug's eff ects are additive to other measures. In the UK Prospective Diabetes Study, 17 a reduction in HbA 1c of 0·9% over 10 years in patients treated with intensive blood glucose control compared with control patients did not result in signifi cant changes in either amputation rate or death from peripheral vascular disease. Similarly, peripheral vascular disease was not signifi cantly reduced by intensive glucose control in patients from the same study who were followed up for up to 20 years, 18 or in patients from the ADVANCE study 19 (the ACCORD study 20 has not published on amputations to date). Neither the HOPE study, 21 which assessed the angiotensin-converting enzyme inhibitor, ramipril, nor the ADVANCE study, 22 which tested intensive blood pressure reduction with perindopril and indapamide, has reported any amputation data so far.
The most common pattern of dyslipidaemia in people with diabetes is hypertriglyceridaemia with or without HR=hazard ratio. Counts for each category of amputation are shown. *Patients were counted only once within each category but may be included in more than one category if they had more than one type of amputation. If a patient had more than one type of amputation, or more than one of the same type of amputation, only the fi rst event of each type was analysed. †For all events, all amputations for each category are counted (Poisson method): the incidence rate ratio, analogous to the hazard ratio, is plotted.
reduced HDL cholesterol concentrations. However, the eff ects of treatment with fenofi brate on the risk of amputation might go beyond the improvements in controlling the lipid profi le, since no lipid variables were associated with the risk of amputation in multivariable analyses. Additionally, the Heart Protection Study, 23 which randomly assigned 5963 people with diabetes to either simvastatin or placebo, showed no diff erence in amputation rates between groups, despite substantial reductions in total cholesterol and LDL cholesterol concentrations and modest changes in triglyceride and HDL cholesterol concentrations in the intervention group compared with controls. This fi nding suggests that the eff ects of fenofi brate in reducing amputation risk are more likely to be non-lipid-mediated and, as such, unaff ected by the diff erent rates of statin use between treatment groups in the FIELD study. Several theoretical mechanisms for the microvascular benefi ts of fenofi brate have been proposed. In a randomised placebo-controlled trial, treatment with fenofi brate was associated with improved endothelialdependent vascular reactivity over 12 weeks, 24 with reductions in markers of endothelial dysfunction and pro-infl ammatory markers, including tumour necrosis factor α, interleukin 6, and interleukin 1β in plasma; another trial also showed that fenofi brate treatment was associated with reduced viscosity. 25 These results need to be substantiated by longer-term studies. In patients with hypertriglyceridaemia or metabolic syndrome, fenofi brate improved fl ow-mediated dilator response to hyperaemia, with increased adiponectin concentrations and improved insulin sensitivity.
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The drug might exert its antiangiogenic eff ects directly, 27 or by reducing tissue ischaemia through these actions. [24] [25] [26] Fenofi brate also activates AMP kinase in endothelial cells via a peroxisome-proliferating receptor-α independent pathway, preventing retinal cell apoptosis, 28 and possibly increasing nitric oxide synthesis. 29 Fenofi brate could also be protective through the inhibition of oxidative stress 30 (current FIELD studies of blood markers of infl ammation and oxidation will help to investigate this mechanism further) and has been reported to have neuroprotective eff ects in rodents, 31 which could be particularly important in view of the key role of neuropathy in risk of amputation.
An amputation due to diabetes occurs around every 30 s somewhere in the world. 32 Amputations substantially impair quality of life 33 and impose a major burden on health-care systems, with annual costs in the UK estimated at about £252 million 34 and in the USA at about US$1648 million. 3 Most of this expenditure is related to type 2 diabetes, with less than 10% accounted for by type 1 diabetes. Indirect costs would further increase these fi gures substantially.
Foot ulcers and infections are also a major source of morbidity, associated with neuropathy, abnormal foot biomechanics, peripheral arterial disease, and poor wound healing. 35 Peripheral sensory neuropathy results in major or repeated minor trauma to the foot (often unnoticed), abnormal weight bearing, and subsequent callus formation and ulceration. Motor and sensory neuropathy leads to abnormal foot muscle mechanics and structural changes in the foot. Autonomic neuropathy results in anhidrosis and altered superfi cial blood fl ow that promotes drying of the skin and fi ssure formation. Peripheral arterial disease and poor wound healing impede the resolution of minor skin breaks, allowing them to enlarge and become infected. 35 Prevention is, therefore, the most essential strategy for avoiding diabetic foot ulcers and amputations; this approach involves identifying patients at high risk, providing education about appropriate foot care, and implementing measures to prevent ulceration (such as protective footwear and podiatry). Such foot care has reduced amputation risk by 45%. 36 Our study lends support to the following predictors of future lower-limb amputation that were previously suggested in a smaller cohort study of 1300 patients with a diff erent study design:
37 a history of previous foot ulcer, longer diabetes duration, presence of neuropathy or peripheral arterial disease, and poor glycaemic control.
Our study also identifi ed height as a major predictor of amputations, with a 1·6-fold increase in risk for every 10 cm increase in height, which is similar to a previous observational report of an odds ratio of 1·8 for each 10 cm increase in height.
38 Two previous studies have described, in a mixed cohort of patients with and without diabetes, that hypercholesterolaemia and hypertension result in worse peripheral arterial disease outcomes. 39, 40 Although in our study these conditions were not independent predictors of amputation risk exclusively, they contributed towards amputation risk indirectly, since peripheral vascular disease was found to be an independent major risk factor.
There are limitations to this study, including the fact that there was no standardised routine testing (for example, angiography or ankle-brachial index) at baseline to assess vascular status, because it was not required by the study protocol. It is therefore possible that some amputations could have been misclassifi ed by the failure to detect large-vessel disease, because of either unreported angiograms, or vascular studies or comorbidities that could have precluded revascularisation. However, if such non-diff erential misclassifi cation bias resulting from missed large-vessel disease had occurred, then the observed reduction with fenofi brate in those with minor amputation without large-vessel disease would likely be an underestimate of the true treatment eff ect in that group (because there was less eff ect seen in those with large-vessel disease).
FIELD is the largest randomised controlled trial of type 2 diabetes mellitus reporting data for amputations, with a very large set of baseline variables. The risks of overall amputation were substantially lower in the fenofi brate group than in the placebo group over 5 years, and the drug had a satisfactory safety profi le (reported elsewhere). 5 The proposed microvascular benefi ts of such treatment are suggested by the signifi cant risk reduction for minor amputations without large-vessel disease. These benefi ts seem additive to any benefi ts arising from good glycaemic control and the use of angiotensinconverting enzyme inhibitors or angiotensin-receptor blockers, and therefore represent an important breakthrough in the prevention of diabetic complications. These fi ndings support the use of fenofi brate, irrespective of the presence of dyslipidaemia, for the treatment of patients with type 2 diabetes who are at high risk for amputation (including those with peripheral vascular disease, existing microvascular complications, and a long duration of diabetes). This approach could help to reduce the substantial morbidity, mortality, and economic burden associated with amputation due to diabetes.
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